The deal is the latest in a string of overseas acquisitions by the Ahmedabad drugmaker as it looks to diversify and strengthen its specialty plays in regulated markets.
2 min read13 May 2026Pharma stocks have been attracting FIIs. Here are three stocks where FIIs have hiked stake in the March 2026 quarter.
4 min read9 May 2026Wockhardt's shares surged 12.55% to ₹1,604 following a profitable Q4FY26 with a net profit of ₹164 crore. Strong revenue growth from biotech and emerging markets fueled performance, with full-year revenue rising to ₹3,373 crore and EBITDA increasing by 51%.
2 min read5 May 2026The Indian stock market experienced a downturn on April 24, as Nifty 50 and BSE Sensex declined amid rising crude oil prices and geopolitical uncertainties. Analysts suggest a flat market opening, recommending shares such as Praj Industries and Mankind Pharma for investors looking to buy.
5 min read24 Apr 2026Lupin's shares are expected to attract investor attention as the company received U.S. FDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets.
1 min read8 Apr 2026The ruling allows generic drugmakers to challenge the original legality of expired patents, potentially shielding them from past damage claims and speeding up the arrival of affordable medicines.
5 min read25 Feb 2026Small-cap stock Sudarshan Pharma has received vital certifications for its manufacturing facility, strengthening its commitment to quality and compliance. The stock trades in the green in the near term.
2 min read19 Feb 2026Here are a list of 5 CDMO stocks that you can add to your watchlist as the industry continues to see good growth.
9 min read11 Feb 2026NGL Fine Chem, a key player in pharmaceutical products, has seen its share price surge from ₹15 to ₹2,282, delivering multibagger gains to its investors.
2 min read9 Feb 2026Sigachi Industries shares rebounded after announcing progress on a new combination of APIs for Cystic Fibrosis, projecting revenue of ₹250 cr annually by FY2026-27. The move enhances growth potential in a market expected to exceed USD 10 bln, focusing on innovative treatments for rare diseases.
1 min read21 Jan 2026Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.